AU2001294192A1 - Solid preparations - Google Patents

Solid preparations

Info

Publication number
AU2001294192A1
AU2001294192A1 AU2001294192A AU9419201A AU2001294192A1 AU 2001294192 A1 AU2001294192 A1 AU 2001294192A1 AU 2001294192 A AU2001294192 A AU 2001294192A AU 9419201 A AU9419201 A AU 9419201A AU 2001294192 A1 AU2001294192 A1 AU 2001294192A1
Authority
AU
Australia
Prior art keywords
solid preparations
preparations
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294192A
Other languages
English (en)
Inventor
Masahiko Koike
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU2001294192A1 publication Critical patent/AU2001294192A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
AU2001294192A 2000-10-06 2001-10-05 Solid preparations Abandoned AU2001294192A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000313106 2000-10-06
JP2000-313106 2000-10-06
JP2000313105 2000-10-06
JP2000-313105 2000-10-06
PCT/JP2001/008785 WO2002030400A1 (fr) 2000-10-06 2001-10-05 Preparations solides

Publications (1)

Publication Number Publication Date
AU2001294192A1 true AU2001294192A1 (en) 2002-04-22

Family

ID=26602026

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294192A Abandoned AU2001294192A1 (en) 2000-10-06 2001-10-05 Solid preparations

Country Status (5)

Country Link
US (1) US7510728B2 (ja)
EP (1) EP1329217A4 (ja)
AU (1) AU2001294192A1 (ja)
CA (1) CA2424770A1 (ja)
WO (1) WO2002030400A1 (ja)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
CA2442311C (en) * 2001-04-26 2009-12-01 Meiji Seika Kaisha Ltd. Amorphous cefditoren pivoxil composition and process for producing the same
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
UA80991C2 (en) * 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
CN1809342A (zh) * 2003-06-25 2006-07-26 诺瓦提斯公司 含有氟伐他汀和羧甲纤维素钙的片剂
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
EP1674083B1 (en) * 2003-10-15 2018-08-01 Fuji Chemical Industry Co., Ltd. Tablet quickly disintegrating in oral cavity
ITRM20030485A1 (it) * 2003-10-22 2005-04-23 Tubilux Pharma S P A Composizione a base di citicolina in associazione con vitamine per la prevenzione ed il trattamento di patolgie oculari.
US20080038341A1 (en) * 2004-01-20 2008-02-14 James Kowalski Direct Compression Formulation And Process
JP2008510835A (ja) * 2004-08-25 2008-04-10 エッセンシャリス，インク． カリウムａｔｐチャンネル開放因子の製剤処方、及びその使用
JP2008528456A (ja) * 2005-01-26 2008-07-31 レツク・フアーマシユーテイカルズ・デー・デー 親油性結晶性物質としてカンデサルタンシレキセチルを含む新規な医薬組成物
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
HUE054887T2 (hu) 2005-06-17 2021-10-28 Wisconsin Alumni Res Found Topikális érösszehúzó készítmények és eljárások sejtek védelmére rák kemoterápia és radioterápia alatt
AU2016202290B2 (en) * 2005-06-17 2017-10-05 Wisconsin Alumni Research Foundation Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
TWI347942B (en) * 2005-06-22 2011-09-01 Lundbeck & Co As H Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
KR101465803B1 (ko) 2005-08-10 2014-11-26 시오노기세이야쿠가부시키가이샤 구강내 붕괴 정제
JOP20180109A1 (ar) * 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
CA2633149C (en) * 2005-12-22 2015-06-30 Takeda Pharmaceutical Company Limited Solid preparation containing an insulin sensitizer
TW200810753A (en) * 2006-04-27 2008-03-01 Takeda Pharmaceutical Solid preparation
CL2007001457A1 (es) * 2006-05-23 2008-01-04 Takeda Pharmaceutical Preparacion oral que comprende pioglitazona o una sal de la misma y un cloruro de metal alcalino, util como hipoglicemiante.
CA2658549A1 (en) * 2006-08-08 2008-02-14 Kissei Pharmaceutical Co., Ltd. Oral disintegrating tablet having masked bitter taste and method for production thereof
EP2063888A4 (en) * 2006-09-05 2009-11-04 Astrazeneca Ab PHARMACEUTICAL COMPOSITION COMPRISING CANDESARTAN CILEXETIL
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP2133096A4 (en) 2007-03-13 2011-11-16 Dainippon Sumitomo Pharma Co IN THE MOUTHING TABLET
ES2830073T3 (es) * 2007-04-11 2021-06-02 Omeros Corp Composiciones y métodos para la profilaxis y el tratamiento de adicciones
US20160331729A9 (en) * 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
GB2453770A (en) * 2007-10-19 2009-04-22 Reckitt Benckiser Healthcare Oral composition comprising a cooling agent
DE102007052070A1 (de) 2007-10-30 2009-05-07 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Candesartancilexetil
MX349677B (es) 2007-11-13 2017-08-08 Meritage Pharma Inc Composiciones corticosteroides.
CN102088959B (zh) * 2008-06-20 2016-05-25 默克专利股份有限公司 可直接压缩的且快速崩解的片剂基质
DK2432452T3 (en) 2009-05-20 2016-10-10 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutically telmisartan drink solution
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
WO2011019043A1 (ja) 2009-08-11 2011-02-17 大日本住友製薬株式会社 ２種以上の粒子を含有する口腔内速崩壊錠
KR101636958B1 (ko) * 2009-09-11 2016-07-06 주식회사 대웅제약 우루소데옥시콜린산-합성하이드로탈사이트-유드라짓 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법
CN107811980B (zh) 2009-10-30 2021-06-18 Ix 生物医药有限公司 快速溶解固体剂型
EP2568971B1 (en) * 2010-05-11 2020-10-14 Mitsubishi Tanabe Pharma Corporation Canagliflozin containing tablets
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
TW201340998A (zh) * 2012-02-29 2013-10-16 Takeda Pharmaceutical 經口劑
CN104080443B (zh) * 2012-03-29 2017-12-12 株式会社大赛璐 含酸式羧甲基纤维素的崩解性颗粒组合物的制法、及该组合物和含该组合物的口腔崩解片剂
CN104010663B (zh) * 2012-09-20 2021-02-19 株式会社大赛璐 含酸式羧甲基纤维素和结晶纤维素的崩解性颗粒组合物及含该组合物的口腔内崩解片剂
WO2015005241A1 (ja) * 2013-07-06 2015-01-15 株式会社ダイセル 超速崩壊錠剤及びその製造方法
WO2017038455A1 (ja) * 2015-09-04 2017-03-09 株式会社ダイセル 超速崩壊錠剤及びその製造方法
CA3001337C (en) 2015-10-09 2023-12-12 Reckitt Benckiser Llc Pharmaceutical formulation
TWI703989B (zh) * 2016-01-18 2020-09-11 日商大賽璐股份有限公司 口腔內保持型崩解性固形製劑、其製造方法、及用於該製造方法之粉體組成物
US11382866B2 (en) * 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
US20240091367A1 (en) 2022-07-29 2024-03-21 Sushma Paul BERLIA Orally disintegrating palatable formulations of drotaverine and method of preparation thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8730011D0 (en) 1987-12-23 1988-02-03 Smithkline Dauelsberg Pharmaceutical compositions
DK0481294T4 (da) * 1990-10-19 2001-06-18 Spirig Ag Fast, hurtigt-opløseligt lægemiddelpræparat indeholdende N-acetylcystein
JP3454517B2 (ja) 1991-04-25 2003-10-06 京都薬品工業株式会社 矯味経口剤
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5785984A (en) * 1993-02-05 1998-07-28 Kao Corporation Taste-modifying method and bitterness-decreasing method
JPH07285868A (ja) 1994-04-13 1995-10-31 Kissei Pharmaceut Co Ltd ピロリジン誘導体を含有する医薬品製剤
FR2722408B1 (fr) 1994-07-15 1996-10-04 Vacher Dominique Nouveau procede de realisation de formes pharmaceutiques seches a delitement quasiment instantane etles formes pharmaceutiques ainsi realisees
DK0922464T3 (da) 1996-07-12 2005-06-06 Daiichi Seiyaku Co Hurtigt desintegrerbare, kompressionsstöbte materialer og fremgangsmåder til fremstilling af samme
JPH10114655A (ja) 1996-10-09 1998-05-06 Kyowa Hakko Kogyo Co Ltd 固形製剤
US5958453A (en) * 1996-10-31 1999-09-28 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility
JPH10236947A (ja) 1997-02-21 1998-09-08 Dai Ichi Seiyaku Co Ltd マスキング剤
JP3770518B2 (ja) 1997-03-28 2006-04-26 エーザイ株式会社 苦味等を隠蔽した経口薬剤
JPH1135486A (ja) * 1997-07-23 1999-02-09 Lion Corp 薬用固形製剤
JP3783993B2 (ja) 1997-07-24 2006-06-07 エーザイ株式会社 製剤組成物及びその製造方法
US6589554B1 (en) * 1998-03-16 2003-07-08 Yamanouchi Pharmaceutical Co., Ltd. Tablets quickly disintegrating in the oral cavity and process for producing the same
JP2000273039A (ja) 1999-01-20 2000-10-03 Taisho Pharmaceut Co Ltd 口腔内崩壊性組成物
JP3310233B2 (ja) * 1999-02-17 2002-08-05 第一工業製薬株式会社 錠剤用崩壊剤
JP2001058944A (ja) * 1999-06-18 2001-03-06 Takeda Chem Ind Ltd 速崩壊性固形製剤
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes

Also Published As

Publication number Publication date
EP1329217A1 (en) 2003-07-23
US7510728B2 (en) 2009-03-31
CA2424770A1 (en) 2003-04-03
US20040033258A1 (en) 2004-02-19
EP1329217A4 (en) 2007-04-04
WO2002030400A1 (fr) 2002-04-18

Similar Documents

Publication Publication Date Title
AU2001294192A1 (en) Solid preparations
AU2001262847A1 (en) Language-understanding
AU2001236005A1 (en) Preparations stabilized over long time
AU2001292739A1 (en) 1-oxorapamycins
AU2000267458A1 (en) Hypercomputer
AU2001254546A1 (en) Aminopiperidines
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001220246A1 (en) Neckphone
AU2002211620A1 (en) Autoanastomosis
AU2001258349A1 (en) Bisacylguanidine
AU2001296577A1 (en) Chlorophyllases
AU2001279754A1 (en) Indoloquinazolinones
AU2002211128A1 (en) Step-bike
AU2001285886A1 (en) 2-guanidino-4-aryl-quinazoline
AU2001290931A1 (en) Ski-snowboard
AU2001258924A1 (en) Microsatellite-aflp
AU2001293852A1 (en) Sulfonylguanidine
AU2002226346A1 (en) 2-aryl-5-trifluoromethylpyridines
AU2001240791A1 (en) Sequence
AU2001281921A1 (en) Bdellosomes
AU2001288102A1 (en) Solid preparations
AU2001246864A1 (en) Hypotensors
AU2001291876A1 (en) Triazolo-epothilones
AU2001272427A1 (en) Solid preparations
AU2002214354A1 (en) Neck-phone